title: Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors.
authors.affiliation: Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. samer.ezziddin@ukb.uni-bonn.de
authors.forename: Samer
authors.initials: S
authors.lastname: Ezziddin
authors.forename: Holger
authors.initials: H
authors.lastname: Lauschke
authors.forename: Michael
authors.initials: M
authors.lastname: Schaefers
authors.forename: Carsten
authors.initials: C
authors.lastname: Meyer
authors.forename: Martijn
authors.initials: M
authors.lastname: van Essen
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Biersack
authors.forename: Dik J
authors.initials: DJ
authors.lastname: Kwekkeboom
authors.forename: Hojjat
authors.initials: H
authors.lastname: Ahmadzadehfar
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D018358:Neuroendocrine Tumors / Q000532:radiotherapy* / Q000601:surgery*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000532:radiotherapy* / Q000601:surgery*; D011300:Preoperative Care / Q000379:methods; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant / Q000379:methods; D016896:Treatment Outcome
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C447941:lutetium Lu 177 dotatate; D015282:Octreotide